---
aliases: /news/clinical-ink-nominated-for-2022-pact-enterprise-awards
archetype: press-release
author:
  - Radhika Narayanan
basePath: /news/
breadcrumbLinks:
  - /
  - /news/
  - ''
breadcrumbs:
  - Home
  - News
  - Clinical ink Nominated for 2022 PACT Enterprise Awards
categories:
  - 'Medigy: Media (Press) Release'
categorySlug:
  - 'medigy: media (press) release'
categoryUrl:
  - topic/medigy-media-press-release
categoryLabel:
  - Media (Press) Release
contentCategories: netspective-medigy-news-curated-content
institution:
  - id: 2442
    title: Clinical Ink
    description: >-
      Clinical Ink is the leader in decentralized clinical trial conduct.
      Lunexis™ is the only platform that enables each customer to define the
      setup that works best for their trial. Patients and clinicians can mix
      modalities, switching from smartphone (BYOD) to tablet to PC as desired.
      Trials can operate on-site, remotely, or utilize a blend of both without
      missing a beat. And from televisits to home health to wearables, our
      platform supports it all.
    alias: /profile /offeror/institution/clinical-ink
    slug: clinical-ink
    url: /profile/offeror/institution/clinical-ink
    logo: 2442-logo.JPEG
offering: null
layOut: news-press-release-single
date: '2022-06-08'
description: >-
  Horsham, Pa.; May 25, 2022 — Clinical ink, a global life science technology
  company, was nominated for Technology Company of the Year by the Philadelphia
  Alliance for Capital and Technologies (PACT) d
favIconImage: null
featuredImage: null
featuredPdf: null
htmlMetaData:
  author: null
  description: null
  generator: null
  viewport: null
  articlemodified_time: null
  articlepublished_time: null
  msvalidate.01: null
  ogdescription: null
  ogimage: null
  ogsite_name: null
  ogtitle: null
  ogtype: null
  ogupdated_time: null
  ogurl: null
  yandex-verification: null
  robots: null
  fbapp_id: null
  oglocale: null
  fbadmins: null
  articlepublisher: null
  google-site-verification: null
  keywords: null
id: 13435
identifier: News
lastMod: '2022-06-07T11:33:56.251494Z'
link:
  brand: clinicalink.com
  href: >-
    https://www.clinicalink.com/clinical-ink-nominated-for-2022-pact-enterprise-awards/
  original: >-
    https://www.clinicalink.com/clinical-ink-nominated-for-2022-pact-enterprise-awards/
href: >-
  https://www.clinicalink.com/clinical-ink-nominated-for-2022-pact-enterprise-awards/
original: >-
  https://www.clinicalink.com/clinical-ink-nominated-for-2022-pact-enterprise-awards/
mastHead: NEWS
mdName: 195a512f-8698-58f1-81b3-f885da49c006.md
openGraphMetaData:
  ogdescription: null
  ogtitle: null
  ogurl: null
  ogimage: null
  ogsite_name: null
  ogtype: null
  ogupdated_time: null
  ogimageheight: null
openProjectCustomFields:
  cleanUrl: >-
    https://www.clinicalink.com/clinical-ink-nominated-for-2022-pact-enterprise-awards/
  medigyTopics:
    - 'Medigy: Media (Press) Release'
  sourceUrl: >-
    https://www.clinicalink.com/clinical-ink-nominated-for-2022-pact-enterprise-awards/
openProjectWorkPackageType: Press Release
searchCategory: News
slug: clinicalink-clinical-ink-nominated-for-2022-pact-enterprise-awards
source: open-project-curations
status: ''
sub: brief
tags:
  - News
title: Clinical ink Nominated for 2022 PACT Enterprise Awards
via: ' '
insights_description: null
insights_name: null
viaLink: null
relatedOfferings: null
twitterMetaData:
  twittercard: null
  twitterdescription: null
  twittertitle: null
  twitterimage: null
  twitterurl: null
---
<p><strong>Horsham, Pa.; May 25, 2022</strong> — Clinical ink, a global life science technology company, was nominated for Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT) during the organization’s 29th annual Enterprise Awards, held May 24, 2022.&nbsp;</p><p>Clinical ink was recognized for pioneering and continually innovating direct data capture technologies, which allow for the measurement of clinical trial patients both in and outside the clinic. Notably, earlier in 2022 the company announced research that strengthens its standing as a critical partner in advancing clinical development for Parkinson’s disease, via the collection of patient data via sensors and at-home wearable assessments.&nbsp;</p><p>Clinical ink was nominated by a panel of judges consisting of executives from the area’s largest life science and healthcare companies, healthcare and technology focused investors, and startup executives.&nbsp;</p><p>“We are incredibly honored to be among the nominees,” says Chief Executive Officer Ed Seguine. “At Clinical ink, our work is rooted in enabling clinical discovery by bringing data, technology, and patient science together. We are proud to be recognized for our technological prowess, as well as our deep industry knowledge and scientific expertise. We will only continue to advance our offerings, ensuring that our partners can better power patient outcomes.”&nbsp;</p><p>Over the past five years, Clinical ink has experienced 40% annual revenue growth. By consistently delivering technology solutions that allow for the collection of complex clinical data, the company has established relationships with the largest and most innovative pharmaceutical sponsors in the industry.&nbsp;&nbsp;</p><p><strong>About Clinical ink&nbsp;</strong>&nbsp;<a href="http://www.clinicalink.com/">Clinical ink</a> is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.&nbsp;</p>